Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biotin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Biotin. Displaying page 1 of 1.
    EudraCT Number: 2019-004360-22 Sponsor Protocol Number: Huntiam Start Date*: 2021-10-22
    Sponsor Name:Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned)
    Full Title: MULTI-TECHNICAL TEST ON THE USE OF COMBINED THERAPY OF THEMIN AND BIOTINE IN PATIENTS WITH HUNTINGTON'S DISEASE
    Medical condition: Huntington´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002113-35 Sponsor Protocol Number: MD1003CT2013-02MS-SPI Start Date*: Information not available in EudraCT
    Sponsor Name:MEDDAY SAS
    Full Title: Effect of MD1003 in spinal progressive multiple sclerosis: a pivotal randomized double blind placebo controlled study
    Medical condition: Progressive spinal multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000698-38 Sponsor Protocol Number: MD1003CT2014-01AMN Start Date*: 2014-08-13
    Sponsor Name:MEDDAY SAS
    Full Title: MD1003 IN ADRENOMYELONEUROPATHY: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY
    Medical condition: Adrenomyeloneuropathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10069075 Adrenomyeloneuropathy without cerebral involvement LLT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-002112-27 Sponsor Protocol Number: MD1003CT2013-01MS-ON Start Date*: Information not available in EudraCT
    Sponsor Name:MEDDAY SAS
    Full Title: Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study
    Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    18.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-005810-31 Sponsor Protocol Number: MD1003CT2015-02-ALS Start Date*: 2016-06-03
    Sponsor Name:MEDDAY PHARMACEUTICALS
    Full Title: Effect of MD1003 in amyotrophic lateral sclerosis: a randomized, double blind placebo controlled study
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001150-15 Sponsor Protocol Number: MD1003CT2015-01-SERENDEM Start Date*: 2016-03-14
    Sponsor Name:MEDDAY PHARMACEUTICALS
    Full Title: SERENDEM study: MD1003 in patients suffering from demyelinating neuropathies, an open label pilot study
    Medical condition: chronic inflammatory demyelinating polyradiculoneuropathy, demyelinating neuropathy associated with immunoglobulin M (IgM) monoclonal gammopathy and antibodies against myelin-associated glycoprotei...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10066137 Anti-MAG neuropathy LLT
    18.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    18.1 100000004850 10008414 Charcot-Marie-Tooth disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002652-33 Sponsor Protocol Number: T-Haplo-for-SCD Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital of Regensburg
    Full Title: A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000700-29 Sponsor Protocol Number: MD1003CT2016-01MS-SPI2 Start Date*: 2017-02-01
    Sponsor Name:MEDDAY PHARMACEUTICALS SA
    Full Title: Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) HU (Completed) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005562-38 Sponsor Protocol Number: M2011-238 Start Date*: 2012-11-13
    Sponsor Name:Miltenyi Biotec GmbH
    Full Title: A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in chi...
    Medical condition: Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000969-37 Sponsor Protocol Number: AN-SCD1121 Start Date*: 2007-10-05
    Sponsor Name:Anthera Pharmaceuticals Incorporated
    Full Title: IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk ...
    Medical condition: Acute Chest Syndrome (ACS) in At-Risk patients with Sickle Cell Disease (SCD) and Vaso-occlusive Crisis (VOC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051895 Acute chest syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004696-22 Sponsor Protocol Number: PANUSCO Start Date*: 2009-09-22
    Sponsor Name:Universitätsklinikum Heidelberg
    Full Title: An Open Label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution versus Best Supportive Nutritional Care in Subjects with Pancreatic Adenocarcinoma Receiving 5-FU plus Oxalip...
    Medical condition: Patients with Pancreatic Adenocarcinoma with progression under Chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005317-68 Sponsor Protocol Number: ACE-CL-208 Start Date*: 2016-05-16
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
    Medical condition: High Risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000440-15 Sponsor Protocol Number: ACE-CL-001 Start Date*: 2014-05-14
    Sponsor Name:Acerta Pharma, BV
    Full Title: A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
    Medical condition: • Chronic Lymphocytic Leukemia • Richter's Syndrome • Prolymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036889 Prolymphocytic leukemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 05:06:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA